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We describe a case of hereditary hypophosphatemic rickets with hypercalciuria (HHRH) in a 32-year-old female with short
stature, chronic pathologic genu valgum deformity, and knee pain who was referred to endocrinology clinic after previous
inconclusive workups. We present imaging spanning 10 years of untreated disease. Biochemical studies showed hypophosphatemia with undetectable ﬁbroblast growth factor 23 (FGF23.) Renal ultrasound revealed bilateral medullary nephrocalcinosis despite no apparent hypercalciuria. Due to concern for HHRH, genetic testing was performed that determined this
patient to be homozygous in the SLC34A3 gene for a previously described missense variant (c.1402C > T, p.Arg468Trp). There was
no known family history of rickets. A bone biopsy with metabolic studies was performed for diagnostic and prognostic reasons.
The histopathological ﬁndings along with tetracycline uptake studies were consistent with a diagnosis of HHRH. Treatment with
phosphorous supplementation and surgical correction of her valgum deformity resulted in resolution of pain, but no change in
bone histomorphometry.

1. Introduction
Hereditary hypophosphatemia rickets with hypercalciuria
(HHRH) is an extraordinarily rare autosomal recessive
disorder with an estimated prevalence of 1/250,000 [1].
Variants in the SLC34A3 gene encoding a sodium-dependent phosphate transporter (NaPi-IIc) have been implicated
as responsible for this disease. The NaPi-IIc transporter is

highly expressed in the nephron’s proximal tubules, and its
dysfunction results in phosphate wasting disorder.
Here, we report a case of HHRH presenting as a genu
valgum deformity with pain in a 32-year-old female with no
fracture history and unremarkable family history for metabolic bone disease. We review the pathophysiology, diagnosis, and treatment of HHRH and contrast HHRH and
other phosphate wasting disorders.
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2. Case Presentation
A 32-year-old Caucasian female presented to endocrinology
clinic with severe left knee pain and a signiﬁcant genu
valgum deformity bilaterally. The patient reported being told
that “she may have had rickets” at the age of 9 but was lost to
follow-up. Ten years prior to this current presentation, she
presented at the age of 22 with painful trochanteric bursitis.
During this clinic appointment, X-ray images showed a
signiﬁcant genu valgum deformity at a Q- angle of 17°
(Figure 1). Deformity correction was suggested at this time
but was not performed. At that time, no endocrinologic
workup was performed.
Now, at the age of 32, a complete medical history was
obtained. She is currently taking over-the-counter vitamin
D3, but no calcium supplementation. She is 155 cm (58.5 kg
and BMI 23.79 kg/m2), her mother is 173 cm, and her father
is 188 cm. She has no siblings or children. She has no fracture
or abnormal dentition history. There is no family history of
rickets or other metabolic bone disease.
On physical examination, there is marked valgus
alignment bilaterally, with left being signiﬁcantly more
prominent. Gait examination showed her left knee knocking
into her right leg. X-ray scans were performed that showed a
Q-angle of 23°, worsened from her presentation 10 years
prior (Figure 1). Bone mineral density scans showed
osteopenia of the left femoral head with normal lumbar
spine density (Figure 2). Pertinent laboratory values displayed hypophosphatemia, elevated total vitamin D and
1,25-dihydroxyvitamin D, undetectable ﬁbroblast growth
factor 23 (FGF23), and low parathyroid hormone (Table 1).
Twenty-four-hour urine showed inappropriately normal
phosphate excretion and normal urine calcium. A renal
ultrasound showed bilateral medullary nephrocalcinosis,
without calculi (Figure 3). HHRH was suspected due to her
described biochemistry and the presence of bilateral renal
calcinosis. Thus, genetic testing was pursued, and this patient
was determined to be homozygous in the SLC34A3 gene for
a previously described missense variant (c.1402C > T,
p.Arg468Trp) (NM_080877.2) [2, 3]. Due to these ﬁndings,
she was started on phosphorous supplementation (K-Phos
Neutral 250 mg TID AC).
A right iliac crest bone biopsy was performed and sent
for metabolic bone studies prior to the initiation of phosphorus. Histopathological ﬁndings included high porosity of
the cortical bone, decreased cancellous bone, and decreased
osteoid surface (Figure 4). Fluorescent light microscopy with
tetracycline labelling showed a decrease in the mineralizing
surface. Some double labels were seen in the subcortical
bone. The distance between double labels was in the lownormal range. These results show previous weakly diﬀuse
tetracycline deposition (Figures 4(e) and 4(f )), determined
to be most likely due to her recent prescription of doxycycline for facial acne therapy which was stopped in advance
of the biopsy. In summary, the metabolic bone biopsy
showed low bone volume with reduced turnover of cancellous bone without evidence of osteomalacia.
Since the diagnosis of HHRH, she continued to receive
phosphorous supplementation; meanwhile, vitamin D was
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stopped. Her abnormal laboratory values have resolved
(Table 1). Her left knee pain has improved signiﬁcantly. Six
months after starting phosphorus supplementation, she
underwent an uncomplicated left total knee arthroplasty
(TKA) leading to gait correction (Figure 5). Biopsy at the
time of surgery showed thin cortical bone and high porosity
without evidence of osteomalacia, not signiﬁcantly changed
in comparison with her previous biopsy (Figure 6).

3. Discussion
The patient in this case initially presented at the age of 9 and
received an ambiguous diagnosis of “rickets.” She did not
receive a deﬁnitive diagnosis and begin correct treatment
until 20 years later. Like other cases in the literature, our case
highlights the protracted diagnostic journey for many of
these patients with incorrect or uncertain diagnoses along
the way [4]. This patient had presented in childhood with leg
pain and genu valgum deformity. To understand the differential diagnosis for deformities such as genu valgum or
“knock knee,” one must ﬁrst understand the natural history
of the alignment of the lower limbs [5]. In newborns and
infants, “bowlegs” (bilateral genu varus) are physiologic.
These become straight by around 18–24 months. By 2 or 3
years, “knock knee” (physiologic genu valgus) develops with
an average Q-angle of about 12°. By 7 years, spontaneous
correction usually occurs to the physiologic alignment of
adult valgus (mean of about 7° in females and 5° in males)
and anything >12° is considered pathological. If valgus is
sustained past this point, it is considered pathological and
can cause signiﬁcant distress, referred pain, and pressure,
causing trochanteric bursitis as seen in this case.
A correct workup for these deformities is essential. If a
patient is misdiagnosed, surgical correction may fail and
cause healing diﬃculties. The diﬀerentialdiagnosis for bilateral genu valgum includes physiologic, renal osteodystrophy (renal rickets), skeletal dysplasia, Morquio syndrome,
spondyloepiphyseal dysplasia, chondroextodermal dysplasia, and metabolic disorders including HHRH. The diﬀerential diagnosis for unilateral genu valgum includes physeal
injury from trauma, infection, or vascular insult, proximal
metaphyseal tibia fracture, benign tumors (ﬁbrous dysplasia,
osteochondromas, and Ollier’s disease), among others [6].
Our patient had bilateral valgus, with unilateral predominance. Thus, a metabolic bone disorder was most likely.
Tieder et al. were the ﬁrst to describe the clinical phenotype of HHRH in a consanguineous Bedouin family [7].
Since then, case reports have been published from individuals from a variety of ethnicities, leading to the realization
that HHRH is likely an underrecognized cause of rickets and
osteomalacia [8]. In fact, patients misdiagnosed with osteoporosis have been later found to have HHRH [4]. Patients
usually present in the ﬁrst years of life with rickets, bone
pain, short stature, and lower extremity deformities. Patients
with this condition can also develop recurrent nephrolithiasis and/or medullary nephrocalcinosis. The classically published biochemical phenotype includes
hypophosphatemia, phosphaturia, hypercalciuria, elevated
1,25-dihydroxyvitamin D levels, and suppressed PTH levels.
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(a)

(b)

Figure 1: Radiographs of lower extremity genu valgus. (a) At age 22, ten years prior to the current presentation, radiography displays genu
valgum of the left knee measuring 17° with a hypoplastic lateral femoral condyle. (b) At current presentation, at age 32, redemonstration of
genu valgum of the left knee measuring 23° with narrowing of the joint compartments at the knees and osteochondral irregularity of the talar
dome on the right.
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Figure 2: Bone mineral density (BMD) scans (current presentation). (a) The BMD within the lumbar spine is 1.140 g/cm2 which corresponds to a Z-score of −0.4. (b) The BMD within the left total hip is 0.807 g/cm2 which corresponds a Z-score of −1.4. The BMD within the
left femoral neck is 0.819 g/cm2 which corresponds to a Z-score of −1.3.

We will discuss each of these electrolyte and endocrinologic
abnormalities in more detail below.
HHRH is caused by variants in the SLC34A3 gene which
codes for the proximal tubular transporter NaPi-IIc. NaPiIIc is one of three known phosphate transporters in the
proximal tubule: NaPi-IIa, NaPi-IIc, and PiT2 [9]. NaPi-IIc
reabsorbs divalent phosphate (HPO2−
4 ) from the ﬁltrate in
exchange of sodium ions. Variants in SLC34A3/NaPi-IIc
lead to impaired phosphate reabsorption and thus phosphate wasting in the urine. At least 40 separate pathogenic
variants in SLC34A3 have been identiﬁed [1]. The inheritance pattern is autosomal recessive and often caused by

compound heterozygotic variants. Interestingly, carriers of a
single SLC34A3 variant display an intermediate phenotype
with increased frequency of renal calculi compared to the
general population [10]. This patient’s parents, presumed to
be carriers, had no history of nephrolithiasis and were of
normal stature.
Phosphate wasting in HHRH leads to elevation of 1,25dihydroxyvitamin D levels, a key clue diﬀerentiating HHRH
from other phosphate wasting disorders. Elevated 1,25dihydroxyvitamin D levels in these patients cause increased
calcium absorption from the gastrointestinal tract which
results in transient hypercalcemia, suppressed PTH levels,
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Table 1: Laboratory values.

Lab test (reference value)
Phosphorus (2.3–4.7 mg/dL)
Calcium (8.5–10.5 mg/dL)
Creatinine (0.57–1.11 mg/dL)
Total vitamin D (25–80 ng/mL)
1,25-Dihydroxy vitamin D (19.9–79.3 pg/mL)
FGF23 (≤180)
Bone-speciﬁc alkaline phosphate
(premenopausal female: 4.5–16.9 μg/L)
Parathyroid hormone (16–77 pg/mL)
Urine phosphorus (400–1,300 mg/24 hr)
Urine calcium (100–300 mg/24 hr)

At presentation
1.7
9.6
0.82
85
154
<50

After 6 months of phosphorus supplementation
2.5
8.9
0.83
56
126
—

12.1

12.7

9
777∗
155

16
—
—

∗

In patients with hypophosphatemia, urinary phosphate excretion above 100 mg/day or a fractional excretion, FEPO4, above 5 percent is indicative of renal
phosphate wasting.

(a)

(b)

Figure 3: Renal ultrasound (current presentation). (a) Left kidney measuring 11.7 cm in length. (b) Right kidney measuring 11.5 cm in
length. Both kidneys have homogenous cortical echoes. The renal pyramids are hyperechoic consistent with bilateral medullar
nephrocalcinosis.

(a)

(b)

(e)

(c)

(f )

(d)

(g)

Figure 4: Iliac crest bone biopsy prior to phosphorus supplementation. Modiﬁed Masson–Goldner trichrome (a)–(e). High porosity of the
cortical bone (a) and decreased cancellous bone volume (b). Low bone turnover and mild hypocellularity of bone marrow (c). Rare osteoid
seam of normal thickness (d) and few osteoclasts (e). Fluorescent light microscopy: few tetracycline label (f ) and evidence of a previous
oxytetracycline label (g).
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(a)

(b)

Figure 5: Postoperative radiographs. Postoperative imaging following corrective left total knee arthroplasty: anterior-posterior (a) and
lateral views (b).

(a)

(b)

Figure 6: Intraoperative surgical biopsy after phosphorus supplementation. Modiﬁed Masson–Goldner trichrome of a femur specimen
obtained at the time of knee arthroplasty displayed thin cortical bone and high porosity (a). Thin trabecula and adipose bone marrow (b). No
signiﬁcant change in comparison with her prior biopsy.

and a compensatory hypercalciuria [11]. Occasionally, an
incidentally discovered hypercalcemia can trigger a diagnostic workup leading to the diagnosis of HHRH. The reduction in PTH-dependent calcium-reabsorption in the
distal renal tubules ultimately leads to nephrolithiasis and/or
nephrocalcinosis. Another diﬀerentiating feature between
HHRH and other phosphate wasting disorders is the low
levels of ﬁbroblast growth factor 23 (FGF23) in HHRH. The
normal physiologic function of FGF23 is the regulation of
phosphate concentration in the blood. FGF23 is secreted by
osteocytes when 1,25-dihydroxyvitamin D levels are elevated. FGF23 then acts on the kidneys by decreasing the
expression of NaPi-IIc [12]. In turn, FGF23 decreases the
reabsorption of phosphate, causing phosphate wasting. In
addition, recent studies have shown that FGF23 may also
suppress 1-alpha-hydroxylase, reducing its ability to activate
vitamin D and therefore impairing calcium absorption and
homeostasis [13].
In evaluating hypophosphatemia, the patient’s levels of
vitamin D, FGF23, and PTH are particularly useful. Vitamin D levels are elevated in HHRH, whereas they are low

or inappropriately normal in conditions of FGF23 excess.
Vitamin D deﬁciency, however, can mask laboratory features of HHRH and therefore must be assessed independently [8, 14, 15]. Hypophosphatemic disorders with
FGF23 excess are more common than HHRH and are
caused by variants directly aﬀecting FGF23 and its metabolism. For example, X-linked hypophosphatemia is
caused by variants in PHEX which is an inactivator of
FGF23 and is approximately ten times more common than
HHRH [16, 17].
Treatment of FGF23-mediated phosphate wasting involves phosphate and vitamin D supplementation. In conditions of FGF23 excess, an emerging treatment option is
Burosumab, an anti-FGF23 IgG1 monoclonal antibody,
which has been recently approved for use in X-linked
hypophosphatemia [18]. Since HHRH is an FGF23-independent disorder, Burosumab would be ineﬀective. Currently, the only treatment for HHRH is long-term
phosphorous supplementation which can singularly cause
remission and rapid correction of bone mineralization capacity. Meanwhile, the addition of active vitamin D
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metabolites can cause symptom deterioration and worsening
of hypercalciuria and nephrolithiasis [14, 19]. Ultimately,
HHRH should be treated with phosphorus supplementation
for at least 6 months before corrective surgery (e.g.,
osteotomy and TKA) is pursued to ensure that bone mineralization is no longer compromised. If not, poor bone
healing and mineralization may occur, causing further
deﬁcits that may be irreversible. Ideally, identiﬁcation of
HHRH in childhood might prevent the need for surgical
correction later in life. The variable clinical presentations of
HHRH, however, may not be recognized until after
childhood.
The constellation of symptoms in HHRH can be variable
in their onset and severity. Patients presenting in childhood
generally have rickets and/or nephrolithiasis. In adulthood,
nephrolithiasis and bone pain are the most common presenting symptoms. The presence of renal calciﬁcations is
more uncommon and is often attributed to inappropriate
treatment of HHRH with vitamin D. The variability in the
age of presentation is due to incomplete penetrance from
various variants and environmental factors [15]. Serum
phosphate is sensitive to dietary intake of phosphate. And, in
turn, the compensatory endocrinologic mechanisms lead to
ﬂuctuating laboratory values [19, 20]. In this case, the renal
ultrasound demonstrating nephrocalcinosis was particularly
pivotal in the diagnosis due to the equivocal urine calcium
measurement. Given the lengthy diﬀerential diagnosis for
phosphate wasting, genetic analysis is generally considered
necessary for a conclusive diagnosis of HHRH.

4. Conclusions
Herein, we presented the ﬁrst reported case of surgical
correction of a genu valgus deformity caused by hereditary
hypophosphatemic rickets with hypercalciuria (HHRH).
HHRH is an underidentiﬁed cause of rickets and osteomalacia and may be misdiagnosed as osteoporosis. We
reviewed phosphate wasting disorders and their distinguishing features.
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